Source: Oxidative Medicine and Cellular Longevity. Unidade: IB
Subjects: DOENÇA DE PARKINSON, MELATONINA, DOENÇAS NEURODEGENERATIVAS, AGENTES DOPAMINÉRGICOS, ANTIOXIDANTES, NEUROCIÊNCIAS
ABNT
MACK, Josiel Mileno et al. Melatoninergic system in Parkinson’s disease: from neuroprotection to the management of motor and nonmotor symptoms. Oxidative Medicine and Cellular Longevity, v. 2016, p. 1-31, 2016Tradução . . Disponível em: https://doi.org/10.1155/2016/3472032. Acesso em: 03 nov. 2024.APA
Mack, J. M., Schamne, M. G., Sampaio, T. B., Pértile, R. A. N., Fernandes, P. A. C. M., Markus, R. P., & Prediger, R. D. (2016). Melatoninergic system in Parkinson’s disease: from neuroprotection to the management of motor and nonmotor symptoms. Oxidative Medicine and Cellular Longevity, 2016, 1-31. doi:10.1155/2016/3472032NLM
Mack JM, Schamne MG, Sampaio TB, Pértile RAN, Fernandes PACM, Markus RP, Prediger RD. Melatoninergic system in Parkinson’s disease: from neuroprotection to the management of motor and nonmotor symptoms [Internet]. Oxidative Medicine and Cellular Longevity. 2016 ; 2016 1-31.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1155/2016/3472032Vancouver
Mack JM, Schamne MG, Sampaio TB, Pértile RAN, Fernandes PACM, Markus RP, Prediger RD. Melatoninergic system in Parkinson’s disease: from neuroprotection to the management of motor and nonmotor symptoms [Internet]. Oxidative Medicine and Cellular Longevity. 2016 ; 2016 1-31.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1155/2016/3472032